The Lancet: April 24, 2014

Marcia Brose discusses results of a phase III trial of the kinase inhibitor sorafenib for treating radioactive iodine-refractory thyroid cancer.
Source: Listen to The Lancet - Category: General Medicine Authors: Source Type: podcasts